New antibiotics in clinical trials for Clostridium difficile

References

• Cohen SH1, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010 May;31(5):431–455.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834.
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Taminiau B, Van Broeck J, et al. Clostridium difficile infection and intestinal microbiota interactions. Microb Pathog. 2015;89:201–209.
   PubMed Web of Science ®Google Scholar
• Shields K, Araujo-Castillo RV, Theethira TG, et al. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59–73.
   PubMed Web of Science ®Google Scholar
• Patel D, Goldman-Levine JD. Fidaxomicin (Dificid) for Clostridium difficile. Am Fam Physician. 2013;87(3):211–212.
   Web of Science ®Google Scholar
• Locher HH, Caspers P, Bruyère T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):901–908.
   PubMed Web of Science ®Google Scholar
• Actelion Pharmaceuticals Ltd press release. Actelion is initiating Phase III clinical development of the novel antibiotic cadazolid in patients suffering from Clostridium difficile associated diarrhea. September 10, 2013 [cited 2016 Jun 29]. Available from: https://www1.actelion.com/en/journalists/news-archive.page?newsId=1728396
   Google Scholar
• U.S. National Institutes of Health ClinicalTrials.gov website. [ cited 2016 Jun 29]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Hubschwerlen C, Specklin J-L 5-Hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials. US8124623 B2. 2012
   Google Scholar
• Rashid MU, Lozano HM, Weintraub A, et al. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe. 2013;20:32–35.
   PubMed Web of Science ®Google Scholar
• Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):892–900.
   PubMed Web of Science ®Google Scholar
• Chilton CH, Crowther GS, Baines SD, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014;69(3):697–705.
   PubMed Web of Science ®Google Scholar
• Locher HH, Ritz D, Schroeder S et al. Cadazolid, a novel quinolonyloxazolidinone antibiotic: mode of action and effect on Clostridium difficile toxin and spore formation. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA. Abstract C1–1347. Washington, DC: American Society for Microbiology; 2012.
   Google Scholar
• Baldoni D, Gutierrez M, Timmer W, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014;69(3):706–714.
   PubMed Web of Science ®Google Scholar
• Seiler P, Enderlin-Paput M, Pfaff P, et al. Cadazolid does not promote intestinal colonization of vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother. 2015;60(1):628–631.
   PubMed Web of Science ®Google Scholar
• Gehin M, Desnica B, Dingemanse J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection. Int J Antimicrob Agents. 2015;46(5):576–581.
   PubMed Web of Science ®Google Scholar
• Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59(10):6266–6273.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Hecht DW, Louie T, et al. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother. 2016;71(1):213–219.
   PubMed Web of Science ®Google Scholar
• LaMarche MJ, Leeds JA, Amaral A, et al. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J Med Chem. 2012;55(5):2376–2387.
   PubMed Web of Science ®Google Scholar
• Leeds JA, Sachdeva M, Mullin S, et al. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother. 2012;56(8):4463–4465.
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam CV, et al. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2012;56(5):2493–2503.
   PubMed Web of Science ®Google Scholar
• Mullane K, Lee C, Bressler A, et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(3):1435–1440.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Sanders IM, et al. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J Antimicrob Chemother. 2013;68(6):1305–1311.
   PubMed Web of Science ®Google Scholar
• Leeds JA, Sachdeva M, Mullin S, et al. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother. 2014;69(1):41–44.
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Leeds JA. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Antimicrob Agents Chemother. 2015;59(2):1252–1257.
   PubMed Web of Science ®Google Scholar
• Ting LS, Praestgaard J, Grunenberg N, et al. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob Agents Chemother. 2012;56(11):5946–5951.
   PubMed Web of Science ®Google Scholar
• Trzasko A, Leeds JA, Praestgaard J, et al. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother. 2012;56(8):4459–4462.
   PubMed Web of Science ®Google Scholar
• Bhansali SG, Mullane K, Ting LS, et al. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(3):1441–1445.
   PubMed Web of Science ®Google Scholar
• Vickers RJ, Tillotson G, Goldstein EJC, et al. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 May 30. pii: S0924-8579(16)30117-0. [Epub ahead of print]. doi:10.1016/j.ijantimicag.2016.04.026
   PubMedGoogle Scholar
• Mann J, Taylor PW, Dorgan CR, et al. The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic-industrial partnership. Medchemcomm. 2015;6(8):1420–1426.
   PubMed Web of Science ®Google Scholar
• Summit Therapeutics press release. Summit Therapeutics announces novel antibiotic ridinilazole (SMT19969) achieves statistical superiority over vancomycin in CoDIFy phase 2 clinical trial for C. difficile infection. November 23, 2015 [cited 2016 Jun 29]. Available from: http://www.summitplc.com/media/press-releases
   Google Scholar
• Bassères E, Endres BT, Khaleduzzaman M, et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May;71(5):1245–1251.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Tyrrell KL, et al. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother. 2013;57(10):4872–4876.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Tyrrell KL. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence. Antimicrob Agents Chemother. 2014;58(2):1187–1191.
   PubMed Web of Science ®Google Scholar
• Freeman J, Vernon J, Vickers R, et al. Susceptibility of Clostridium difficile isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators. Antimicrob Agents Chemother. 2015;60(1):689–692.
   PubMed Web of Science ®Google Scholar
• Corbett D, Wise A, Birchall S, et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother. 2015;70(6):1751–1756.
   PubMed Web of Science ®Google Scholar
• Baines SD, Crowther GS, Freeman J, et al. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother. 2015;70(1):182–189.
   PubMed Web of Science ®Google Scholar
• Weiss W, Pulse M, Vickers R. In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother. 2014;58(10):5714–5718.
   PubMed Web of Science ®Google Scholar
• Sattar A, Thommes P, Payne L, et al. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. J Antimicrob Chemother. 2015;70(6):1757–1762.
   PubMed Web of Science ®Google Scholar
• Vickers R, Robinson N, Best E, et al. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis. 2015;15:91.
   PubMed Web of Science ®Google Scholar
• Vickers RJ, Tillotson GS, Nathan R, et al. Ridinilazole for Clostridium difficile Infections: safety and efficacy compared with vancomycin from the CoDIFy phase 2 trial. Presented at the 26^th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2016; Amsterdam, Netherlands, abstract 2771.
   Google Scholar
• Yin N, Li J, He Y, et al. Structure-activity relationship studies of a series of semisynthetic lipopeptides leading to the discovery of surotomycin, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficile-associated diarrhea. J Med Chem. 2015;58(12):5137–5142.
   PubMed Web of Science ®Google Scholar
• Alam MZ, Wu X, Mascio C, et al. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob Agents Chemother. 2015;59(9):5165–5170.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, Mcdermott LA. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother. 2012;56(6):3448–3452.
   PubMed Web of Science ®Google Scholar
• Citron DM, Goldstein EJ. Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile. Diagn Microbiol Infect Dis. 2011;70(4):554–556.
   PubMed Web of Science ®Google Scholar
• Chilton CH, Crowther GS, Todhunter SL, et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother. 2014;69(9):2426–2433.
   PubMed Web of Science ®Google Scholar
• Adams HM, Li X, Mascio C, et al. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species. Antimicrob Agents Chemother. 2015;59(7):4139–4147.
   PubMed Web of Science ®Google Scholar
• Mascio CT, Chesnel L, Thorne G, et al. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 2014;58(7):3976–3982.
   PubMed Web of Science ®Google Scholar
• Bouillaut L, Mcbride S, Sorg JA, et al. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro. Antimicrob Agents Chemother. 2015;59(7):4199–4205.
   PubMed Web of Science ®Google Scholar
• Mascio CT, Mortin LI, Howland KT, et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother. 2012;56(10):5023–5030.
   PubMed Web of Science ®Google Scholar
• Patino H, Stevens C, Louie T, et al. (2011) Efficacy and safety of the lipopeptide CB-183,315 for the treatment of C. difficile infection. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy 2011 Sep 17–20; Chicago (IL). Poster 230.
   Google Scholar
• Chandorkar G, Zhan Q, Donovan J, et al. Pharmacokinetics of surotomycin from phase 1 single ascending dose study in healthy volunteers. Present at IDWeek. 2013, San Francisco, CA, USA, October 4, 2013. Poster 716.
   Google Scholar
• Citron DM, Tyrrell KL, Dale SE, et al. Impact of surotomycin on the gut microbiota of healthy volunteers in a phase 1 clinical trial. Antimicrob Agents Chemother. 2016;60(4):2069–2074.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S154–61.
   PubMed Web of Science ®Google Scholar